Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neurobiochemical Cross-talk Between COVID-19 and Alzheimer’s Disease
Mohammad Azizur Rahman, Kamrul Islam, Saidur Rahman, et al.
Molecular Neurobiology (2020) Vol. 58, Iss. 3, pp. 1017-1023
Open Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

Could SARS-CoV-2 Spike Protein Be Responsible for Long-COVID Syndrome?
Theoharis C. Theoharides
Molecular Neurobiology (2022) Vol. 59, Iss. 3, pp. 1850-1861
Open Access | Times Cited: 128
Cognitive, EEG, and MRI features of COVID-19 survivors: a 10-month study
Giordano Cecchetti, Federica Agosta, Elisa Canu, et al.
Journal of Neurology (2022) Vol. 269, Iss. 7, pp. 3400-3412
Open Access | Times Cited: 121
COVID-19 and Alzheimer’s disease: how one crisis worsens the other
Xiaohuan Xia, Yi Wang, Jialin Zheng
Translational Neurodegeneration (2021) Vol. 10, Iss. 1
Open Access | Times Cited: 119
The Impact of COVID-19 On Comorbidities: A Review Of Recent Updates For Combating It
Jonaid Ahmad Malik, Sakeel Ahmed, Mrunal Shinde, et al.
Saudi Journal of Biological Sciences (2022) Vol. 29, Iss. 5, pp. 3586-3599
Open Access | Times Cited: 88
The roles of Eph receptors, neuropilin-1, P2X7, and CD147 in COVID-19-associated neurodegenerative diseases: inflammasome and JaK inhibitors as potential promising therapies
Hamidreza Zalpoor, Abdullatif Akbari, Azam Samei, et al.
Cellular & Molecular Biology Letters (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 83
Dementia and COVID-19, a Bidirectional Liaison: Risk Factors, Biomarkers, and Optimal Health Care
Sofia Toniolo, Marta Scarioni, Francesco Di Lorenzo, et al.
Journal of Alzheimer s Disease (2021) Vol. 82, Iss. 3, pp. 883-898
Closed Access | Times Cited: 76
Diverse Immunological Factors Influencing Pathogenesis in Patients with COVID-19: A Review on Viral Dissemination, Immunotherapeutic Options to Counter Cytokine Storm and Inflammatory Responses
Ali A. Rabaan, Shamsah H. Al-Ahmed, Mohammed Garout, et al.
Pathogens (2021) Vol. 10, Iss. 5, pp. 565-565
Open Access | Times Cited: 74
Emerging COVID-19 Neurological Manifestations: Present Outlook and Potential Neurological Challenges in COVID-19 Pandemic
Saikat Dewanjee, V. Jayalakshmi, Rajkumar Singh Kalra, et al.
Molecular Neurobiology (2021) Vol. 58, Iss. 9, pp. 4694-4715
Open Access | Times Cited: 65
ACE2 expression in rat brain: Implications for COVID-19 associated neurological manifestations
Vito S. Hernández, Mario A. Zetter, Enrique C. Guerra, et al.
Experimental Neurology (2021) Vol. 345, pp. 113837-113837
Open Access | Times Cited: 62
COVID-19 causes neuronal degeneration and reduces neurogenesis in human hippocampus
Amir‐Hossein Bayat, Helia Azimi, Meysam Hassani Moghaddam, et al.
APOPTOSIS (2022) Vol. 27, Iss. 11-12, pp. 852-868
Open Access | Times Cited: 47
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms
Feng Chen, Yan‐Ting Chen, Yongxiang Wang, et al.
Translational Neurodegeneration (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 45
Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms
Pei Huang, Linyuan Zhang, Yuyan Tan, et al.
Translational Neurodegeneration (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 30
Depressive and Neurocognitive Disorders in the Context of the Inflammatory Background of COVID-19
Eliza Dąbrowska, Beata Galińska-Skok, Napoleon Waszkiewicz
Life (2021) Vol. 11, Iss. 10, pp. 1056-1056
Open Access | Times Cited: 43
SARS-CoV-2 Exacerbates Beta-Amyloid Neurotoxicity, Inflammation and Oxidative Stress in Alzheimer’s Disease Patients
Luigi Chiricosta, Agnese Gugliandolo, Emanuela Mazzon
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 24, pp. 13603-13603
Open Access | Times Cited: 43
Unravelling the connection between COVID-19 and Alzheimer’s disease: a comprehensive review
Shah Rezlan Shajahan, Suresh Kumar, Muhammad Danial Che Ramli
Frontiers in Aging Neuroscience (2024) Vol. 15
Open Access | Times Cited: 6
COVID-19 as a Risk Factor for Alzheimer’s Disease
Mahdieh Golzari-Sorkheh, Donald F. Weaver, Mark A. Reed
Journal of Alzheimer s Disease (2022) Vol. 91, Iss. 1, pp. 1-23
Open Access | Times Cited: 28
COVID-19 and Neurodegenerative Diseases: Prion-Like Spread and Long-Term Consequences
Narjes Baazaoui, Khalid Iqbal
Journal of Alzheimer s Disease (2022) Vol. 88, Iss. 2, pp. 399-416
Open Access | Times Cited: 26
Dementia Clinical Care in Relation to COVID-19
Angelo Bianchetti, Renzo Rozzini, Luca Bianchetti, et al.
Current Treatment Options in Neurology (2022) Vol. 24, Iss. 1, pp. 1-15
Open Access | Times Cited: 25
COVID-19 delirium and encephalopathy: Pathophysiology assumed in the first 3 years of the ongoing pandemic
Kyohei Otani, Haruko Fukushima, Kunitaka Matsuishi
Brain Disorders (2023) Vol. 10, pp. 100074-100074
Open Access | Times Cited: 16
COVID-19 and Alzheimer’s Disease: A Literature Review
Louis Hardan, Dimitar Filtchev, Ratiba Kassem, et al.
Medicina (2021) Vol. 57, Iss. 11, pp. 1159-1159
Open Access | Times Cited: 32
The Altered Anatomical Distribution of ACE2 in the Brain With Alzheimer’s Disease Pathology
Huan Cui, Si Su, Yan Cao, et al.
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 30
Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management
Debmalya Barh, Alaa A. A. Aljabali, Murtaza M. Tambuwala, et al.
Biomedicines (2021) Vol. 9, Iss. 5, pp. 556-556
Open Access | Times Cited: 29
Can SARS-CoV-2 Infection Exacerbate Alzheimer’s Disease? An Overview of Shared Risk Factors and Pathogenetic Mechanisms
Chiara Villa, Eleonora Rivellini, Marialuisa Lavitrano, et al.
Journal of Personalized Medicine (2022) Vol. 12, Iss. 1, pp. 29-29
Open Access | Times Cited: 22
COVID-19 and neurological sequelae: Vitamin D as a possible neuroprotective and/or neuroreparative agent
Sebastián García Menéndez, Virna Margarita Martín Giménez, Michael F. Holick, et al.
Life Sciences (2022) Vol. 297, pp. 120464-120464
Open Access | Times Cited: 20
The amplification of CNS damage in Alzheimer's disease due to SARS-CoV2 infection
Gerard J. Nuovo, David Suster, Dwitiya Sawant, et al.
Annals of Diagnostic Pathology (2022) Vol. 61, pp. 152057-152057
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top